TNDM — Tandem Diabetes Care, Inc.
Is TNDM overbought or oversold? Here is the current MarketMoodz read.
Tandem Diabetes Care, Inc. (TNDM) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Devices) last closed at $17.06. The rating moved from Overbought to Oversold on November 17, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$17.06
- Last changeMoved from Overbought to Oversold on November 17, 2026
- SectorHealthcare
- IndustryMedical Devices
See all oversold Healthcare stocks →
AI analysis
Tandem Diabetes Care occupies a meaningful position in the insulin pump and automated insulin delivery market with product-level strengths around CGM integration and consumable-driven recurring revenue. Short-term headwinds include heightened competition after recent FDA clearances for competitors, visible insider selling, and a more uncertain reimbursement/regulatory backdrop. Growth catalysts include uptake of automated insulin-delivery software, international expansion, and stronger channel execution through specialty distributors. Overall, the outlook is balanced: upside exists if product adoption and recurring revenue accelerate, but execution, competitive intensity and payer dynamics create meaningful near-term downside risks.
Key factors
- Position in the insulin pump market with established pump platforms and CGM integration that support recurring consumable revenue
- Recent competitive pressure from Medtronic (MiniMed Fit tubeless pump FDA clearance) increases near-term product competition and go-to-market challenges
- Secular demand for diabetes management devices and continued adoption of automated insulin delivery support medium-term revenue upside
- Distribution and specialty pharmacy dynamics likely to influence prescription flows and sales mix
- Recent insider Form 4 filings suggesting insider selling, which can weigh on sentiment in the near term
- Regulatory and reimbursement environment (Medicare/MA changes) could affect access and unit economics
Risks
- Intensifying competition from large device makers (Medtronic, Insulet, others) leading to pricing pressure and market-share erosion
- Regulatory and reimbursement headwinds (Medicare Advantage program integrity actions, payer scrutiny) that could reduce reimbursements or slow upgrades
- Execution risk on product launches, software updates, and CGM integration that are core to differentiation
- Supply chain or manufacturing disruptions that could constrain device shipments
- Liquidity and profitability risk if revenue growth slows and operating losses continue (potential need for capital raises)
- Negative investor sentiment from insider selling or weaker-than-expected quarterly results
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for TNDM — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.